---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-005923"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:53:06.208367+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anika Q3 rev $38.8M (-7% YoY), net loss $29.9M; restructures, sells Arthrosurface, plans Parcus divestiture

## Summary
- Revenue $38.8M (-7% YoY), net loss $29.9M ($2.03/sh); adj net loss $3.8M ($0.25/sh).
- Integrity Implant System grew 40%+ sequentially, >500 surgeries since launch, Regenerative Solutions up 17%.
- Exiting Arthrosurface (sold) and Parcus Medical (divestiture planned) to focus on HA technology and Commercial Channel.
- Updated 2024 guidance: Commercial Channel +14% to +19%, OEM -8% to -10%, Adj EBITDA $16-18M; restructuring charges $3-5M cash, $27-29M non-cash.
- First Hyalofast PMA module filed Oct 28; Cingal NDA path progress including acquisition of Aristospan NDA.

## SEC filing metadata
- accession: 0001171843-24-005923
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184324005923/0001171843-24-005923-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184324005923/f8k_103124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-005923
- JSON: https://secwatch.observer/filing/0001171843-24-005923.json
- Plain text: https://secwatch.observer/filing/0001171843-24-005923.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.